Show simple item record

dc.contributor.authorGhosh, Anna K
dc.contributor.authorDazzi, H
dc.contributor.authorThatcher, Nick
dc.contributor.authorMoore, M
dc.date.accessioned2010-07-22T08:46:15Z
dc.date.available2010-07-22T08:46:15Z
dc.date.issued1989-03-15
dc.identifier.citationLack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2. 1989, 43 (3):410-4 Int. J. Canceren
dc.identifier.issn0020-7136
dc.identifier.pmid2784419
dc.identifier.doi10.1002/ijc.2910430311
dc.identifier.urihttp://hdl.handle.net/10541/108136
dc.description.abstractA phase-I/II study of recombinant interleukin 2 (rIL-2) was performed in 31 melanoma patients. The first dose of rIL-2 was given intrasplenically followed 4 hr later by an i.v. dose and 3 further i.v. doses on alternate days. Three courses of treatment were planned at 3-week intervals. The maximum tolerated single dose was 11 x 10(6) Cetus U/m2. Haematological and immunological data were available on 20 patients. Post-treatment response to rIL-2 therapy was evident from (i) a rapid depletion of peripheral blood lymphocytes (PBL) with a rebound at 4-7 days (2 times pre-treatment values); (ii) an increase in the number of IL-2 receptor-positive lymphocytes (4-15 times pre-treatment values); (iii) an increase in the number of "positive" patients with cytotoxic (anti-K562) peripheral blood mononuclear cells (PBMC) from 30% to 80%; (iv) amplified killing of K562 by positive patients in relation to pre-treatment values; and (v) the induction of PBMC cytotoxicity (in 45% of patients) against the NK-resistant, LAK-sensitive target, Mel I. Partial clinical responses to rIL-2 treatment were observed in 4 patients, but these were not reflected in the PBMC LAK activity or the other parameters examined.
dc.language.isoenen
dc.subjectSkin Canceren
dc.subject.meshCytotoxicity, Immunologic
dc.subject.meshDrug Evaluation
dc.subject.meshHumans
dc.subject.meshInterleukin-2
dc.subject.meshKiller Cells, Natural
dc.subject.meshLeukocyte Count
dc.subject.meshLeukocytes, Mononuclear
dc.subject.meshLymphocytes
dc.subject.meshMelanoma
dc.subject.meshPhenotype
dc.subject.meshReceptors, Interleukin-2
dc.subject.meshRecombinant Proteins
dc.subject.meshSkin Neoplasms
dc.titleLack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign, Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK.en
dc.identifier.journalInternational Journal of Canceren
html.description.abstractA phase-I/II study of recombinant interleukin 2 (rIL-2) was performed in 31 melanoma patients. The first dose of rIL-2 was given intrasplenically followed 4 hr later by an i.v. dose and 3 further i.v. doses on alternate days. Three courses of treatment were planned at 3-week intervals. The maximum tolerated single dose was 11 x 10(6) Cetus U/m2. Haematological and immunological data were available on 20 patients. Post-treatment response to rIL-2 therapy was evident from (i) a rapid depletion of peripheral blood lymphocytes (PBL) with a rebound at 4-7 days (2 times pre-treatment values); (ii) an increase in the number of IL-2 receptor-positive lymphocytes (4-15 times pre-treatment values); (iii) an increase in the number of "positive" patients with cytotoxic (anti-K562) peripheral blood mononuclear cells (PBMC) from 30% to 80%; (iv) amplified killing of K562 by positive patients in relation to pre-treatment values; and (v) the induction of PBMC cytotoxicity (in 45% of patients) against the NK-resistant, LAK-sensitive target, Mel I. Partial clinical responses to rIL-2 treatment were observed in 4 patients, but these were not reflected in the PBMC LAK activity or the other parameters examined.


This item appears in the following Collection(s)

Show simple item record